Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Specific peripheral B cell tolerance defects in patients with multiple sclerosis.
Overcoming barriers in progressive multiple sclerosis research.
The NF-κB regulator MALT1 determines the encephalitogenic potential of Th17 cells.
Extoxnet (extension toxicology network), 4-aminopyridine
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (LIBRETTO)
Sanofi withdraws Campath in US and EU
Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection.
Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease.
US top court denies Israel's Teva Pharmaceuticals stay in Copaxone patent fight
Regional Susceptibility to TNF-α Induction of Murine Brain Inflammation via Classical IKK/NF-κB Signalling.
Rescue Therapy Using Rituximab for Multiple Sclerosis.
Safety issue puts daclizumab in doubt for MS
Epigenetic mechanisms in multiple sclerosis and the major histocompatibility complex (MHC).
Receptos Reports Positive Phase 2 Results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis
Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.
Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs.
Novartis gains approval for Gilenya® as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia
Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain.
BRIEF-AB Science says DSMB recommends continuation of phase 3 masitinib study
Multiple sclerosis.
Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis.
JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level.
The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service.
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation.

Pages